LLY earnings track record
Beat analyst EPS estimates in 5 of the last 5 reported quarters, averaging a +22.73% surprise. The most recent result moved the stock +4.86% in the following session.
| Quarter | Reported | EPS est. | EPS actual | Surprise | Next session |
|---|---|---|---|---|---|
| Q2 2026 | 2026-08-05bmo | $6.07 | $8.38 | ▲ +38.14% | ▲ +4.86% |
| Q1 2026 | — | $6.73 | $8.55 | ▲ +27.04% | — |
| Q4 2025 | — | $6.74 | $7.54 | ▲ +11.92% | — |
| Q3 2025 | — | $5.75 | $7.02 | ▲ +22.05% | — |
| Q2 2025 | — | $5.51 | $6.31 | ▲ +14.50% | — |
Recent LLY events
- 2026-08-26NewsChartMillEli Lilly (NYSE:LLY) Demonstrates High-Growth Leadership and Momentum
- 2026-08-24NewsChartMillEli Lilly (NYSE:LLY): A Dividend Quality Pick with Sustainable Growth
- 2026-08-23NewsYahooPrediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here’s Why.
- 2026-08-21NewsChartMillEli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup
- 2026-08-18NewsSeekingAlphaOmniAb: Lilly-Style Partners Are Paying Attention To This Early-Stage Biotech
- 2026-08-17EarningsBenzingaEli Lilly Canada Says Continues To Take Action To Address Promotion And Sale Of Unapproved And Illegal Retatrutide Products In Canada; Disagrees With Characterizations In Canada Revenue Agency’s Application; Will Respond Formally Through Court Process In Due Course
- 2026-08-17NewsBenzingaOmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments
- 2026-08-17NewsBenzingaWhy Is Omniab Stock Rallying After Eli Lilly Deal?
- 2026-08-14EarningsYahoo5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
- 2026-08-13NewsYahooEli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy